Newark, DE, U.S. and Nanjing, China, April 10, 2025 — Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets，BSI-721, a novel ADC drug molecule targeting CDH17, will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 25 to 30，2025.
"We are delighted to present Bision latest research data at AACR. BSI-721 has demonstrated promising biological activity and functionality in preclinical studies, supporting the continued advancement of our preclinical research efforts," said Kedan Lin, Ph.D., Chief Development Officer and President of Biosion US. We look forward to sharing the key data of these important therapeutic assets with the oncology research community at AACR.”
BSI-721 is a novel antibody-drug conjugate (ADC) targeting cadherin 17 (CDH17) in gastrointestinal cancers.The molecule consists of a fully humanized anti-CDH17 monoclonal antibody (mAb) with monomethyl auristatin E (MMAE) via a cleavable peptide linker. In CDH17-high gastric cancer model (SNU-5), treatment with BSI-721 resulted in significant tumor regression (with achievement of partial response) and tumor growth inhibition (TGI). BSI-721 also demonstrated a significant TGI in CDH17-moderate/low pancreatic cancer model (AsPC1). These data collectively demonstrate BSI-721's strong therapeutic potential for GI malignancies with varying expression levels of CDH17.
Time：April 29, 2024, 9:00 AM - 12:30 PM
Location: Poster Section 34
Poster Board Number: 21
Published Abstract Number: 4723
About Biosion
Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide. With its “discover-development-partnership” model, the company has forged 10 global collaborations, advancing seven clinical-stage assets, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Biosion operates across the US, China, and Australia. Learn more at www.Biosion.com.
BIOSION ALL RIGHTS RESERVED.
Newark, DE, U.S. and Nanjing, China, April 10, 2025 — Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets，BSI-721, a novel ADC drug molecule targeting CDH17, will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 25 to 30，2025.
"We are delighted to present Bision latest research data at AACR. BSI-721 has demonstrated promising biological activity and functionality in preclinical studies, supporting the continued advancement of our preclinical research efforts," said Kedan Lin, Ph.D., Chief Development Officer and President of Biosion US. We look forward to sharing the key data of these important therapeutic assets with the oncology research community at AACR.”
BSI-721 is a novel antibody-drug conjugate (ADC) targeting cadherin 17 (CDH17) in gastrointestinal cancers.The molecule consists of a fully humanized anti-CDH17 monoclonal antibody (mAb) with monomethyl auristatin E (MMAE) via a cleavable peptide linker. In CDH17-high gastric cancer model (SNU-5), treatment with BSI-721 resulted in significant tumor regression (with achievement of partial response) and tumor growth inhibition (TGI). BSI-721 also demonstrated a significant TGI in CDH17-moderate/low pancreatic cancer model (AsPC1). These data collectively demonstrate BSI-721's strong therapeutic potential for GI malignancies with varying expression levels of CDH17.
Time：April 29, 2024, 9:00 AM - 12:30 PM
Location: Poster Section 34
Poster Board Number: 21
Published Abstract Number: 4723
About Biosion
Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide. With its “discover-development-partnership” model, the company has forged 10 global collaborations, advancing seven clinical-stage assets, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Biosion operates across the US, China, and Australia. Learn more at www.Biosion.com.
BIOSION ALL RIGHTS RESERVED.